Point-of-Care Molecular COVID Testing: Understanding the Benefits
Since early 2020, the concept of diagnostic testing has become a prime focal point for the...
AACC Spotlight: SEKISUI Diagnostics' Trends and Announcements
At the American Association of Clinical Chemistry 2023, Erica Blight, VP Client Services, Clinical...
Preparing for the Respiratory Season: Insights from Scott Adams & Jonathan Overbey at AACC Anaheim
{% module_block module "widget_bdfea3b4-b852-4d87-bbbf-09bbd81f6ec8" %}{% module_attribute...
An unprecedented Strep A season
After an unprecedented infection season, Strep A finally on the decline in the UK
The...
Made in the USA: It Matters!
Everywhere, backups
Given a choice between a product made in the U.S. and an identical one made...
Testing for STIs declined during the pandemic
We Can Do Better, Public Health Experts Say
Each year there are an estimated 376 million new...
Insights From The Bench: The challenges of DNA polymerase selection for viral point of care testing
Page content:
Combining two technologies to broaden rapid molecular test platform horizons
...
Turning the Tide on Presenteeism
Page Content:
COVID-19 May Influence How Seasonal Infections are Diagnosed and Managed
- A...
Point-of-Care Testing for Emerging Respiratory Diseases
The human toll of COVID-19 has demonstrated the necessity – and difficulty – of quickly identifying
What Can We Expect This Coming Flu Season?
SEKISUI Diagnostics’ National Accounts Director, Jonathan Overbey talks with Ian Fardy from...